Reviewer's report

**Title:** Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice.

**Version:** 1 **Date:** 1 December 2008

**Reviewer:** Okezie I Aruoma

**Reviewer's report:**

The reference deriving the assertion for the long-term administration of HemoHIM should be presented, as the authors indicate data not shown, this need to be substantiaed either way.

Page 10, Result section, Figure 4c is the wrong Figure. Similarly for Figure 3A and B on page 11.

Page 13 lines 8-12 needs amending. Similarly for page 14 lines 2-4.

Page 14 line 14-17 is a repetition of the introductory comments.

The conclusion made by the authors point to the need for them to probe and report with this paper the possible mechanism of protection. Does CDDP affect the first line antioxidant defences and does HemoHIM modulate these in any way?

**Level of interest:** An article of importance in its field

**Quality of written English:** Not suitable for publication unless extensively edited

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I declare that I have no competing interests